Idexx Laboratories Inc. (NASDAQ:IDXX) shares reached a new 52-week high on Tuesday . The company traded as high as $95.50 and last traded at $94.51, with a volume of 149,621 shares changing hands. The stock had previously closed at $94.60.

IDXX has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Idexx Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, July 4th. TheStreet raised Idexx Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, April 29th. Canaccord Genuity reaffirmed a “buy” rating and set a $85.00 price target (up from $80.00) on shares of Idexx Laboratories in a research report on Tuesday, April 19th. Credit Suisse Group AG increased their price target on Idexx Laboratories from $80.00 to $85.00 and gave the company an “outperform” rating in a research report on Wednesday, April 13th. Finally, CL King initiated coverage on Idexx Laboratories in a research report on Friday, April 1st. They set a “neutral” rating for the company. Five analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $81.25.

The stock has a 50 day moving average price of $90.30 and a 200-day moving average price of $79.82. The stock has a market capitalization of $8.38 billion and a price-to-earnings ratio of 45.22.

Idexx Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Friday, April 29th. The company reported $0.51 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.04. The firm had revenue of $417.55 million for the quarter, compared to analysts’ expectations of $403.48 million. During the same quarter in the previous year, the business earned $0.49 EPS. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. On average, analysts predict that Idexx Laboratories Inc. will post $2.21 EPS for the current fiscal year.

In other news, Director William T. End sold 4,924 shares of the firm’s stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $85.87, for a total transaction of $422,823.88. Following the completion of the transaction, the director now owns 63,578 shares in the company, valued at $5,459,442.86. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Several hedge funds and institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Idexx Laboratories by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,331,556 shares of the company’s stock worth $461,697,000 after buying an additional 60,129 shares during the last quarter. Brown Advisory Inc. raised its position in shares of Idexx Laboratories by 3.9% in the fourth quarter. Brown Advisory Inc. now owns 723,728 shares of the company’s stock worth $52,775,000 after buying an additional 26,847 shares during the last quarter. American Capital Management Inc. raised its position in shares of Idexx Laboratories by 19.6% in the fourth quarter. American Capital Management Inc. now owns 647,856 shares of the company’s stock worth $47,242,000 after buying an additional 106,310 shares during the last quarter. State of Wisconsin Investment Board raised its position in shares of Idexx Laboratories by 0.4% in the fourth quarter. State of Wisconsin Investment Board now owns 308,544 shares of the company’s stock worth $22,499,000 after buying an additional 1,126 shares during the last quarter. Finally, Howland Capital Management LLC raised its position in shares of Idexx Laboratories by 2.3% in the fourth quarter. Howland Capital Management LLC now owns 300,331 shares of the company’s stock worth $21,900,000 after buying an additional 6,737 shares during the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.